Page 14 - Flipbook

•Co-primary Endpoint: OS With Durvalumab vs
Platinum based chemotherapy vs durvalumab in front line UC

Chemotherapy in the PD-L1 High Population

1.0

Durvalumab (n=209) Chemotherapy (n=207)

0.8 Median OS, months (95% CI) 14.4 (10.4–17.3) 12.1 (10.4–15.0)

HR (95% CI) 0.89 (0.71–1.11)
Probability of OS 0.6 51% 36%
55%
0.3039
Log-rank P value*

0.4

29%
0.2
Durvalumab

Chemotherapy
0.0

0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51

Time from randomisation (months)
Number at risk

Durvalumab 209 176 143 123 112 97 87 81 74 68 66 63 61 39 19 6 1 0
Chemotherapy 207 186 161 126 101 86 74 66 57 51 48 44 42 27 16 8 2 0

14
*Considered statistically significant if p < 0.0301.